NCT02516423 · MORE INFO

Limitations, agreements, and source contact

Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone · Source last updated 2026-06-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee: false
restrictive Agreement: false

limitations And Caveats

description: Due to early study closure, patients were followed for less time than was protocol specified to determine the symptomatic myeloma progression free-survival (SMPFS) rate. The protocol specifies 5 years of follow-up, however arm 2 patients were followed until SMPFS or between 4.5 months to 3.5 years.

point Of Contact

email: mahindra.anuj@scrippshealth.org
organization: Scripps Health
phone: 858-554-8788
title: Anuj Mahindra, M.D.

Complete source fields

certain Agreement

pi Sponsor Employee: false
restrictive Agreement: false

limitations And Caveats

description: Due to early study closure, patients were followed for less time than was protocol specified to determine the symptomatic myeloma progression free-survival (SMPFS) rate. The protocol specifies 5 years of follow-up, however arm 2 patients were followed until SMPFS or between 4.5 months to 3.5 years.

point Of Contact

email: mahindra.anuj@scrippshealth.org
organization: Scripps Health
phone: 858-554-8788
title: Anuj Mahindra, M.D.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice